Hemodynamic and hormonal effects of quinaprilat in patients with congestive heart failure*

Abstract

Single and multiple intravenous doses of 0.5 to 10 mg quinaprilat are well-tolerated and produce favorable dose-dependent hemodynamic effects and hormonal changes consistent with those expected of an ACE inhibitor in patients with NYHA class III and IV congestive heart failure.

Haemodynamic effects of intravenous quinaprilat in comparison to sodium nitroprusside in patients with chronic heart failure

“…A study by Mitrovic et al [10,11] determined that quinaprilat increased cardiac index by 25% in patients with heart failure. Müller et al examined the effects of intravenous quinaprilat in patients undergoing coronary artery bypass surgery.…”

“…The plasma half-life of quinaprilat is 2 h in healthy male subjects [9]. In a previous study, the haemodynamic effects of quinaprilat in patients with severe heart failure proved beneficial, although moderate [10,11].…”